G2GBio Registers Japanese Patent for 'Mass Production Manufacturing Platform Technology for Sustained-release Microparticles'

- Enhancing safety by removing residual solvents and significantly extending the shelf life of pharmaceuticals

- Patents registered in 12 countries including the United States, EU, and other major medical markets

G2GBio, a specialized pharmaceutical company in the development of sustained-release drugs, announced on the 23rd that it has registered a patent in Japan for a mass production manufacturing method of microparticles capable of accommodating various active pharmaceutical ingredients (APIs).

The patented technology involves removing residual solvents from the microparticles containing the active pharmaceutical ingredients. According to G2GBio, this technology not only increases the safety of pharmaceuticals by reducing residual solvent content but also significantly improves stability, almost without any change in the form of microparticles, thereby dramatically extending the shelf life of the pharmaceuticals. Additionally, the ability to produce in large quantities using small-scale equipment is another advantage.

With the acquisition of this patent in Japan, G2GBio has successfully registered patents in major medical markets such as the United States, European Union (EU), China, and other countries. In addition to these major countries, patents for the mass production manufacturing method of sustained-release microparticles have been completed in a total of 12 countries including Australia, South Africa, India, Russia, Mexico, Brazil, and Canada.

G2GBio emphasized that the patented technology can be applied to all types of active pharmaceutical ingredients, including but not limited to donepezil for dementia treatment, semaglutide for diabetes and obesity treatment, and tirzepatide. Therefore, it is a patent applicable to all active pharmaceutical ingredients.

Hee-yong Lee, CEO of G2GBio, stated, "With this foundational technology, we can apply sustained-release technology to various types of pharmaceuticals, including small-molecule drugs and peptide drugs." He added, "The successful completion of Phase 1 clinical trials for sustained-release dementia treatment drugs in Canada and the initiation of discussions with global pharmaceutical companies for technology transfer of sustained-release diabetes and obesity treatment drugs are also thanks to this foundational technology."

Meanwhile, in April last year, G2GBio signed a comprehensive cooperation agreement with global pharmaceutical companies to provide contract development organization (CDO) services using microparticles, and in October, inspections of Good Manufacturing Practice (GMP) facilities were conducted with another global pharmaceutical company for technology transfer of sustained-release diabetes and obesity treatment drugs.